AI Scientist at Abata Therapeutics

Brisbane, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Drug Discovery, PharmaceuticalsIndustries

Requirements

PhD in Computer Science, Machine Learning, Computational Chemistry, or a related field
Strong publication record in top-tier conferences or journals (e.g., NeurIPS, ICLR, ICML, Nature, Science, Cell)
5+ years of research experience, including postdoctoral or industry settings, with a track record of leading high-impact AI projects
Deep expertise in modern deep learning frameworks (e.g., PyTorch, JAX) and large-scale model training on GPUs or distributed systems
Demonstrated experience at the intersection of AI and molecular sciences (e.g., cheminformatics, molecular docking, protein modeling)
Proven ability to mentor junior researchers and work collaboratively in interdisciplinary environments
Strong communication skills, with experience presenting complex technical work to diverse audiences
Being an active contributor to the open-source or research community is a plus

Responsibilities

Lead research and development of state-of-the-art deep learning models for molecular modeling, generative chemistry, or related applications
Partner with cross-functional teams in biology, chemistry, and clinical sciences to identify key problems and design innovative AI-driven solutions
Mentor and support a growing team of AI scientists and engineers through technical guidance and collaborative leadership
Publish high-impact research and represent Xaira’s scientific leadership in the broader AI/biotech community
Contribute to technical strategy and the long-term vision for AI within Xaira

Skills

Deep Learning

Machine Learning

Molecular Modeling

Generative Chemistry

Generative AI

Protein Design

Antibody Therapeutics

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free